[2]
Heal DJ,Smith SL,Gosden J,Nutt DJ, Amphetamine, past and present--a pharmacological and clinical perspective. Journal of psychopharmacology (Oxford, England). 2013 Jun;
[PubMed PMID: 23539642]
Level 3 (low-level) evidence
[3]
Nehlig A,Daval JL,Debry G, Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain research. Brain research reviews. 1992 May-Aug;
[PubMed PMID: 1356551]
[4]
Calipari ES,Ferris MJ, Amphetamine mechanisms and actions at the dopamine terminal revisited. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2013 May 22;
[PubMed PMID: 23699503]
[5]
Meyer JS, 3,4-methylenedioxymethamphetamine (MDMA): current perspectives. Substance abuse and rehabilitation. 2013;
[PubMed PMID: 24648791]
Level 3 (low-level) evidence
[6]
Nutt D,King LA,Saulsbury W,Blakemore C, Development of a rational scale to assess the harm of drugs of potential misuse. Lancet (London, England). 2007 Mar 24;
[PubMed PMID: 17382831]
[7]
Docherty JR,Alsufyani HA, Pharmacology of Drugs Used as Stimulants. Journal of clinical pharmacology. 2021 Aug;
[PubMed PMID: 34396557]
[8]
Volkow ND,Fowler JS,Wang G,Ding Y,Gatley SJ, Mechanism of action of methylphenidate: insights from PET imaging studies. Journal of attention disorders. 2002;
[PubMed PMID: 12685517]
[9]
Persky AM,Berry NS,Pollack GM,Brouwer KL, Modelling the cardiovascular effects of ephedrine. British journal of clinical pharmacology. 2004 May;
[PubMed PMID: 15089807]
[10]
Trinh KV,Kim J,Ritsma A, Effect of pseudoephedrine in sport: a systematic review. BMJ open sport
[PubMed PMID: 27900142]
Level 1 (high-level) evidence
[11]
Fiidow OA,Minhat HS,Zulkefli NAM,Ahmad N, A systematic review on risk factors for khat chewing among adolescents in the African continent and Arabian Peninsula. PloS one. 2022
[PubMed PMID: 35113927]
Level 1 (high-level) evidence
[14]
Bruening AB,Perez M,Ohrt TK, Exploring weight control as motivation for illicit stimulant use. Eating behaviors. 2018 Aug;
[PubMed PMID: 29886378]
[17]
Fairman KA,Davis LE,Peckham AM,Sclar DA, Diagnoses of Cardiovascular Disease or Substance Addiction/Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling? Drugs - real world outcomes. 2018 Mar
[PubMed PMID: 29305714]
[18]
Pliszka S,AACAP Work Group on Quality Issues., Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2007 Jul
[PubMed PMID: 17581453]
Level 2 (mid-level) evidence
[19]
Fayyad J,De Graaf R,Kessler R,Alonso J,Angermeyer M,Demyttenaere K,De Girolamo G,Haro JM,Karam EG,Lara C,Lépine JP,Ormel J,Posada-Villa J,Zaslavsky AM,Jin R, Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. The British journal of psychiatry : the journal of mental science. 2007 May;
[PubMed PMID: 17470954]
[20]
Suen LW, Davy-Mendez T, LeSaint KT, Riley ED, Coffin PO. Emergency department visits and trends related to cocaine, psychostimulants, and opioids in the United States, 2008-2018. BMC emergency medicine. 2022 Feb 4:22(1):19. doi: 10.1186/s12873-022-00573-0. Epub 2022 Feb 4
[PubMed PMID: 35120449]
[21]
Lo KB,Virk HUH,Lakhter V,Ram P,Gongora C,Pressman G,Figueredo V, Clinical Outcomes After Treatment of Cocaine-Induced Chest Pain with Beta-Blockers: A Systematic Review and Meta-Analysis. The American journal of medicine. 2018 Dec 16;
[PubMed PMID: 30562494]
Level 2 (mid-level) evidence